217 related articles for article (PubMed ID: 18316617)
1. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.
Hegedus B; Banerjee D; Yeh TH; Rothermich S; Perry A; Rubin JB; Garbow JR; Gutmann DH
Cancer Res; 2008 Mar; 68(5):1520-8. PubMed ID: 18316617
[TBL] [Abstract][Full Text] [Related]
2. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
Zhu Y; Harada T; Liu L; Lush ME; Guignard F; Harada C; Burns DK; Bajenaru ML; Gutmann DH; Parada LF
Development; 2005 Dec; 132(24):5577-88. PubMed ID: 16314489
[TBL] [Abstract][Full Text] [Related]
5. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma.
Solga AC; Gianino SM; Gutmann DH
Oncogene; 2014 Jan; 33(3):289-99. PubMed ID: 23318450
[TBL] [Abstract][Full Text] [Related]
6. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.
Banerjee S; Crouse NR; Emnett RJ; Gianino SM; Gutmann DH
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15996-6001. PubMed ID: 21896734
[TBL] [Abstract][Full Text] [Related]
10. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
13. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
Banerjee S; Byrd JN; Gianino SM; Harpstrite SE; Rodriguez FJ; Tuskan RG; Reilly KM; Piwnica-Worms DR; Gutmann DH
Cancer Res; 2010 Feb; 70(4):1356-66. PubMed ID: 20124472
[TBL] [Abstract][Full Text] [Related]
14. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.
Daginakatte GC; Gianino SM; Zhao NW; Parsadanian AS; Gutmann DH
Cancer Res; 2008 Dec; 68(24):10358-66. PubMed ID: 19074905
[TBL] [Abstract][Full Text] [Related]
15. Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.
Banerjee S; Gianino SM; Gao F; Christians U; Gutmann DH
Mol Cancer Ther; 2011 Feb; 10(2):279-91. PubMed ID: 21216928
[TBL] [Abstract][Full Text] [Related]
16. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
17. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
18. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Momota H; Nerio E; Holland EC
Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
[TBL] [Abstract][Full Text] [Related]
19. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.
Pong WW; Higer SB; Gianino SM; Emnett RJ; Gutmann DH
Ann Neurol; 2013 Feb; 73(2):303-8. PubMed ID: 23424002
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.
Daginakatte GC; Gutmann DH
Hum Mol Genet; 2007 May; 16(9):1098-112. PubMed ID: 17400655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
